These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 25776529)

  • 41. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
    BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.
    Fairhurst RA; Knoepfel T; Buschmann N; Leblanc C; Mah R; Todorov M; Nimsgern P; Ripoche S; Niklaus M; Warin N; Luu VH; Madoerin M; Wirth J; Graus-Porta D; Weiss A; Kiffe M; Wartmann M; Kinyamu-Akunda J; Sterker D; Stamm C; Adler F; Buhles A; Schadt H; Couttet P; Blank J; Galuba I; Trappe J; Voshol J; Ostermann N; Zou C; Berghausen J; Del Rio Espinola A; Jahnke W; Furet P
    J Med Chem; 2020 Nov; 63(21):12542-12573. PubMed ID: 32930584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
    Xie H; Alem Glison DM; Kim RD
    Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
    Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
    Shao M; Chen X; Yang F; Song X; Zhou Y; Lin Q; Fu Y; Ortega R; Lin X; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
    J Med Chem; 2022 Mar; 65(6):5113-5133. PubMed ID: 35271262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma.
    Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN
    Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
    Li X; Lu W; Kharitonenkov A; Luo Y
    J Intern Med; 2024 Mar; 295(3):292-312. PubMed ID: 38212977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
    Ezzat S; Zheng L; Winer D; Asa SL
    Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
    Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
    J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
    Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
    Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.
    Nie W; Lu Y; Pan C; Gao J; Luo M; Du J; Wang J; Luo P; Zhu H; Che J; He Q; Dong X
    Bioorg Chem; 2022 Apr; 121():105673. PubMed ID: 35217375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
    Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
    Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
    [No Abstract]   [Full Text] [Related]  

  • 56. N'-Alkylaminosulfonyl Analogues of 6-Fluorobenzylideneindolinones with Desirable Physicochemical Profiles and Potent Growth Inhibitory Activities on Hepatocellular Carcinoma.
    Chen X; Yang T; Deivasigamani A; Shanmugam MK; Hui KM; Sethi G; Go ML
    ChemMedChem; 2015 Sep; 10(9):1548-58. PubMed ID: 26214403
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
    Guo C; Zhou N; Lu Y; Mu M; Li Z; Zhang X; Tu L; Du J; Li X; Huang D; Xu Q; Zheng X
    Biomed Pharmacother; 2024 Jan; 170():115955. PubMed ID: 38048735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression.
    Huang J; Qiu M; Wan L; Wang G; Huang T; Chen Z; Jiang S; Li X; Xie L; Cai L
    Cell Physiol Biochem; 2018; 45(4):1690-1699. PubMed ID: 29490293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of 1,6-Naphthyridin-2(1
    Zhang X; Wang Y; Ji J; Si D; Bao X; Yu Z; Zhu Y; Zhao L; Li W; Liu J
    J Med Chem; 2022 Jun; 65(11):7595-7618. PubMed ID: 35635004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.